Jacqueline Shriver
Women's Health · Saint Marys, OHNPI 1083606610
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,333 of the $1,507 with a category attached, or 88.5%. 21 manufacturers reported payments, led by Astellas Pharma US Inc at 25.1% of the total. Reporting peaked in 2023 at $436 and has fallen 68.3% since, to $138 in 2025.
Across 85 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$378
- Exeltis, USA Inc.$184
- Agile Therapeutics, Inc.$109
- Novo Nordisk$94
- Therapeuticsmd, Inc.$88
- AbbVie$85
- plus $569 from 15 others
What the payments were for
- Food & beverage$1,33388%
- Education$17412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 16 | $378 |
| Exeltis, USA Inc. | 11 | $184 |
| Agile Therapeutics, Inc. | 6 | $109 |
| Novo Nordisk | 6 | $94 |
| Therapeuticsmd, Inc. | 6 | $88 |
| AbbVie | 6 | $85 |
| Sumitomo Pharma America, Inc. | 5 | $84 |
| Pfizer | 5 | $75 |
| Biogen | 1 | $65 |
| Amgen | 4 | $64 |
| Bayer | 3 | $46 |
| Hologic Sales And Service, LLC | 2 | $44 |
| Coopersurgical, Inc. | 2 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $26 |
| Organon | 3 | $24 |
| Avion Pharmaceuticals | 2 | $23 |
| Scynexis, Inc. | 1 | $20 |
| Radius Health, Inc. | 1 | $16 |
| Myovant Sciences Inc. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
How this compares
$1,507 in reported general payments places this provider in the 85th percentile of 333 women's health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 79 | $2,531 |
| Solifenacin Succinate | 16 | $930 |
| ValacyclovirValacyclovir Hcl | 22 | $476 |
| Raloxifene Hcl | 17 | $365 |
| Oxybutynin Chloride ErOxybutynin Chloride | 15 | $259 |
| Amitriptyline Hcl | 15 | $179 |
| Nystatin | 14 | $167 |
| Alendronate Sodium | 24 | $85 |
| Fluconazole | 11 | $44 |
Paid to pharmacies, not to this prescriber.
Other women's health in Saint Marys
- Courtney ArnFranklin$195K
- Carrie van ZantBrookville$21K
- Cindy FarinaCleveland$10K
- Kathryn Lowry-CollinsLebanon$9K
- Angalesia RuckerCleveland$9K
- Vivian RuszkiewiczColumbus$6K
- Lauren ZugaWarren$6K
- Lisa LeeseOregon$5K
- Carrie BottiggiMayfield Heights$5K
- Tammy LawsonZanesville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.